Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Yen, Hsuan; Chang, Yu Tung; Yee, Fui Jun; Huang, Yu Chen

doi:10.1007/s40257-020-00565-5

Cited by 14 publications

(13 citation statements)

References 67 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In summary, we have drawn several conclusions from the literature on metformin and the gut microbiota from 2012 to 2022. Metformin, an old drug for the treatment of T2DM, [ 46 , 50 ] not only has hypoglycemic effects, but also has the effects of anti-aging, [ 51 ] weight loss, [ 52 ] cardiovascular protection, [ 53 ] improvement of polycystic ovary syndrome, [ 54 ] tumor inhibition, [ 55 , 56 ] anti-inflammation, [ 57 ] reversal of pulmonary fibrosis [ 58 ] and reversal of cognitive dysfunction. [ 59 ] In addition, metformin can improve intestinal flora, restore the proportion of intestinal flora, and play a positive regulatory role in the intestinal immune system.…”

Section: Discussionmentioning

confidence: 99%

Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review

Shu,

Li,

et al. 2023

Medicine

View full text Add to dashboard Cite

Background: Metformin is an old drug used for the treatment of type 2 diabetes mellitus and can play a variety of roles by regulating the gut microbiota. The number of research articles on metformin in the gut microbiota has increased annually; however, no bibliometric tools have been used to analyze the research status and hot trends in this field. This study presents a bibliometric analysis of publications on metformin and gut microbiota. Methods: We searched the Web of Science core collection database on June 8, 2023, for papers related to metformin and gut microbiota from 2012 to 2022. We used Microsoft Excel 2021, VOSviewer1.6.19, CiteSpace 6.2.4, and R software package “bibliometrix” 4.0.0 to analyze the countries, institutions, authors, journals, citations, and keywords of the included publications. Results: We included 517 papers, and the trend in publications increased over the last 11 years. The 517 articles were from 57 countries, including 991 institutions and 3316 authors, and were published in 259 journals. China led all countries (233 papers) and the most influential institution was the Chinese Academy of Sciences (16 papers). PLOS ONE (19 papers) was the most popular journal, and Nature (1598 citations) was the most cited journal. Li and Kim were the 2 most published authors (six papers each), and Cani (272 co-citations) was the most co-cited author. “Metabolites,” “aging,” and “intestinal barrier” were emerging topics in this field. Conclusions: This bibliometric study comprehensively summarizes the research trends and progress of metformin and gut microbiota, and provides new research topics and trends for studying the effects of metformin on gut microbiota in different diseases.

show abstract

Section: Discussionmentioning

confidence: 99%

Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review

Shu,

Li,

et al. 2023

Medicine

View full text Add to dashboard Cite

show abstract

“…For example, metformin improves IR in subjects with PCOS or type-2 diabetes mellitus and reduces androgen levels and related esthetic issues such as acne and increased BMI. Furthermore, it has beneficial effects on menstrual cycle regularization [ 31 , 32 , 33 ]. However, a metformin-based clinical approach is not free of concerns, including its lack of efficacy or specificity in some patients, side effects observed in long-term treatments, and the safety of its administration during pregnancy [ 34 , 35 ].…”

Section: Changing the Therapeutic Rationalementioning

confidence: 99%

A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?

Unfer

Dinicola

Russo³

2023

IJMS

View full text Add to dashboard Cite

A recent evaluation of the published data regarding the PCOS topic has highlighted a paradox in the definition of this condition. Even though the name of the syndrome refers to ovarian dysfunction, it seems that patients diagnosed with PCOS are more likely affected by an endocrine and metabolic issue. The term PCOS might not be appropriate to indicate the phenotypes described by the Rotterdam criteria, since the only phenotype with a gynecological issue alone is PCOS phenotype D. This novel perspective regarding how PCOS is currently defined leads the way to a reinterpretation of the entire pathological context and the treatment prescribed, such as inositols. A new point of view on the etiopathogenesis of the disease completely changes the current meaning of PCOS and consequently the therapeutic rationale evaluated to date.

show abstract

“…In addition to lifestyle modification, estrogen–progestin oral contraceptives and biguanide (metformin), are the first choice of therapy for women with PCOS [ 33 , 57 ]. The first line of drug, oral contraceptives has been used to manage endocrine imbalance while treatment with biguanide has effectively reduced blood glucose, insulin resistance, and androgen level, thereby improving endocrinometabolic status of individuals with PCOS, although with side effect profile which causes poor compliance and discontinuation of these therapies [ 15 , 43 ].…”

Section: Introductionmentioning

confidence: 99%

Acetate ameliorates ovarian mitochondrial dysfunction in letrozole-induced polycystic ovarian syndrome rat model by improving mitofusin-2

Olaniyi,

Areloegbe

2024

J Physiol Sci

View full text Add to dashboard Cite

Androgen excess and metabolic abnormality largely contribute to the pathogenesis of polycystic ovarian syndrome (PCOS), which primarily precipitates ovarian dysfunction and infertility in reproductive-age women. Impaired mitochondrial function and epigenetic alteration have been linked to the development of PCOS. However, it is unknown whether acetate would exert a therapeutic effect on ovarian mitochondrial dysfunction in PCOS. Herein, the study hypothesized that acetate reverses ovarian mitochondrial dysfunction in experimental PCOS rat model, possibly through modulation of mitofusin-2 (MFn2). Eight-week-old female Wistar rats were randomized into four groups (n = 5). Induction of PCOS was performed by 1 mg/kg letrozole (p.o.), administered for 21 days. Thereafter, the rats were treated with acetate (200 mg/kg; p.o.) for 6 weeks. The PCOS rats demonstrated androgen excess, multiple ovarian cysts, elevated anti-mullerian hormone and leptin and decreased SHBG, adiponectin and 17-β estradiol with corresponding increase in ovarian transforming growth factor-β1. Additionally, inflammation (tumor growth factor and nuclear factor-kB), elevated caspase-6, decreased hypoxia-inducible factor-1α and elevated histone deacetylase-2 (HDAC2) were observed in the ovaries of PCOS rats, while mitochondrial abnormality with evidence of decreased adenosine triphosphate synthase and MFn2 was observed in rats with PCOS. Treatment with acetate reversed the alterations. The present results collectively suggest that acetate ameliorates ovarian mitochondrial abnormality, a beneficial effect that is accompanied by MFn2 with consequent normalization of reproductive-endocrine profile and ovarian function. Perhaps, the present data provide hope for PCOS individuals that suffer infertility.

show abstract

Metformin Therapy for Acne in Patients with Polycystic Ovary Syndrome: A Systematic Review and Meta-analysis

Cited by 14 publications

References 67 publications

Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review

Bibliometrics and visual analysis of metformin and gut microbiota from 2012 to 2022: A systematic review

A PCOS Paradox: Does Inositol Therapy Find a Rationale in All the Different Phenotypes?

Acetate ameliorates ovarian mitochondrial dysfunction in letrozole-induced polycystic ovarian syndrome rat model by improving mitofusin-2

Contact Info

Product

Resources

About